DDX17

Across TCGA pan-cancer cohorts, DDX17 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DDX17 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DDX17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DDX17 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUAD, BRCA, and UCEC are the cancer types where DDX17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.127	0.750	<.001	24	view →
BRCA	OS	Median	III,IV	0.320	0.833	.010	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.024	8	view →
SKCM	DFS	Median	III,IV	0.710	0.239	.027	4	view →
LIHC	DFS	Median	All	0.100	0.553	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DDX17–LUAD (OS)

Open the LUAD breakdown →